heterozygous carriers of this mutation, which was absent in all 68 control chromosomes tested from Turkish donors ( Figure 1 and data not shown). This mutation alters the F3 PTB-containing integrin binding subdomain of Kindlin-3. Notably, Kindlin-3 is expressed in the same locus of CDGI (11q13) and the 2 genes are 503 029 bp apart, whereas other Kindlins are expressed on other chromosomes. None of the patients suffered from nonhematopoietic abnormalities associated with other Kindlin deficiencies.
Taken together, the LAD-III phenotype reported by us could manifest a combined defect in both upstream and downstream integrin regulatory effectors, namely, CalDAG-GEFI and Kindlin-3, respectively. Our findings predict a potential role for Kindlin-3 in regulating integrin activation in both platelets and leukocytes. Although extremely rare, the presence of identical mutations in 2 functional genes within the same locus in 3 Turkish families may suggest a common ancestor allele carrying both of these mutations. To our knowledge this is a first report of multiple mutations in 2 separate genes which function within a similar signaling axis in a key biologic process. Additional LAD-III cases can serve as ideal model systems to address the cooperative roles of CDGI Rap-1 signaling, talin1, and Kindlin-3 in integrin activation on different hematopoietic cell types.
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